Project Grant R01CA287491
Award Date
9/4/24
Completion Date
8/31/29
Dollars Obligated
$720K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) provides $1,408,844 to the Sloan-Kettering Institute for Cancer Research to characterize the diagnostic and therapeutic potential of DLL3-targeting agents for treating high-grade neuroendocrine carcinomas of the lung and prostate. The key objectives are to evaluate a DLL3-targeted radiolabeled monoclonal antibody (89Zr-DFO-SC16.56) for PET imaging of DLL3 expression in tumor...
This federal Project Grant award of $1,313,806.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The key focus is on developing and translating chimeric antigen receptor (CAR) T-cell therapies targeting the cancer-associated antigen mesothelin for the treatment of solid tumors, particularly malignant pleural mesothelioma. The research aims to...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to conduct comprehensive molecular and clinical characterization of acute and chronic neurotoxicity following chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The $1,220,394 award to the Sloan-Kettering Institute for Cancer Research, spanning from September 2024 to August 2029, will investigate the pathogenesis of acute immune...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cellinfinity Bio Inc. to evaluate next-generation CAR-T cell therapies for renal cell carcinoma (kidney cancer). The key products/services to be delivered include: Developing novel engineered CAR-T cells with genetic modifications (PRDM1 exon 3 deletion, CTLA-4 cytoplasmic tail fusion) to enhance CAR-T cell proliferation, reduce exhaustion, and improve anti-tumor activity...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $692,072 to The University of Texas Southwestern Medical Center to develop novel theranostic agents for managing aggressive subtypes of prostate cancer. The key products and services to be delivered include: Synthesizing PSMA-targeted poly(amidoamine) (PAMAM) dendrimer-based theranostic agents capable of concurrent delivery of imaging,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a phase I clinical trial to investigate the use of CSPG4-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of head and neck squamous cell carcinoma (HNSCC). The $627,456 award, effective December 1, 2024 through November 30, 2029, will fund a single-center, open-label study to evaluate the safety and preliminary efficacy of the CSPG4.CAR-T cells in adult patients...
This $406,520 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of novel, targeted nanotherapies for the treatment of advanced prostate cancer. The key products and services to be delivered include: Synthesis of targeted glycodendrimer nanoplatforms (TGDNs) with varying levels of prostate-specific membrane antigen (PSMA) ligands to enable selective delivery of high payloads of chemotherapeutics to prostate...
The National Cancer Institute awarded a $392,410 Project Grant (CFDA 93.398 Cancer Research Manpower) to Weill Medical College of Cornell University to conduct research aimed at understanding the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The three-year grant, which begins on July 1, 2024 and runs through June 30, 2027, will support the development of an organoid-based allograft platform to modulate the expression of a key transcriptional...
This $627,474 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at the Dana-Farber Cancer Institute (DFCI) to develop innovative epigenomic approaches for early detection and monitoring of neuroendocrine prostate cancer (NEPC) and enzalutamide resistance. The key objectives are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies to detect NEPC and predict enzalutamide...
The National Cancer Institute (NCI) awarded a 5-year, $432,837.14 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Stanford University. The funding will support research to define the key CAR T cell subsets that mediate efficacy in large B-cell lymphoma (LBCL) patients and overcome an immune suppression mechanism that limits CAR T cell therapy. The project aims to use single-cell sequencing and methylation analyses to pinpoint optimal CAR T cell clones and uncover the...